Project Grant R01MH135896
Award Date
12/20/24
Completion Date
10/31/29
Dollars Obligated
$641K
Federal Agency
National Institute of Mental Health
Federal Grant Program
93.242
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
This $1,363,635 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) will fund a multi-site study to investigate the pathophysiology and treatment mechanisms of premenstrual dysphoric disorder (PMDD). The study will examine fluctuations in GABAergic neurosteroids, GABA-A receptor subunit expression, and enzyme expression in women with PMDD, both with and without low-dose SSRI treatment. Key objectives...
This Project Grant award of $485,915 from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) aims to examine three key aspects of GABAergic function in women with premenstrual dysphoric disorder (PMDD): 1) GABAergic neurosteroid fluctuations, particularly allopregnanolone and its isomers, 2) GABA-A receptor subunit expression, and 3) GABAergic neurosteroidogenic enzyme expression. The multi-site study will assess 288 women...
This Project Grant award from the National Institute of Mental Health (NIMH) under CFDA 93.242 Mental Health Research Grants provides $3,392,617 to develop a portable, low-cost, point-of-care microfluidic system for rapid pharmacogenomic screening of patients with major depressive disorder (MDD). The system will analyze patient buccal swabs to determine their CYP enzyme metabolizer status, allowing physicians to optimize SSRI medication selection and dosing within one hour, avoiding the...
This federal Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants program (CFDA 93.242), aims to identify immunobiological mechanisms underlying the development of depression during the perimenopause transition. The $919,453 award will fund a multi-site study over 5 years to: 1) determine plasma tryptophan metabolite and cytokine patterns in perimenopausal depression; 2) define epigenetic mechanisms in lymphocytes that confer...
This federal Project Grant award of $2,199,102.00 from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants (CFDA 93.242) program will fund the "MOMGENES FIGHT PPD: EXPANDING TO INCREASE PARTICIPATION FROM DIVERSE ANCESTRIES" research project. The project aims to systematically investigate the genomic risk factors for postpartum depression (PPD) and their interplay with major environmental contributors, with a focus on increasing participation from...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $729,821 to the University of Alabama at Birmingham (UAB) to study the role of long non-coding RNAs (lncRNAs) in the pathogenesis of major depressive disorder (MDD). The research aims to mechanistically examine how nuclear lncRNA regulation of 3D chromatin organization and epigenomic reprogramming contribute to transcriptional repatterning in the...
This federal Project Grant award, funded by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), will support a large-scale, single-cell characterization of the molecular and cellular networks regulating mood in major depressive disorder (MDD). The $2,220,017 award to the Lieber Institute for Brain Development will enable the identification of transcriptomic changes associated with MDD across 800 human postmortem samples from the...
This federal Project Grant award from the National Institute of Mental Health (NIMH) under CFDA Program 93.242 Mental Health Research Grants provides $563,934 in funding to Tufts University School of Medicine from September 2024 to June 2029. The funding supports research to examine the role of membrane progesterone receptors (MPRs) in mediating the effects of neuroactive steroids, such as allopregnanolone, on neuronal excitability and tonic inhibition in the hippocampus. The research aims to...
This Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) provides $779,842 to evaluate the use of biomarkers to guide treatment decisions for first-episode psychosis (FEP) patients. The study aims to develop a clozapine decision support tool by characterizing 410 FEP patients using brain imaging, genetic tests for weight gain and agranulocytosis risk, and then conducting a randomized controlled trial to assess...
This $196,776 federal Project Grant award from the National Institute of Mental Health (NIMH) under CFDA 93.242 - Mental Health Research Grants will support a study by the Emma Pendleton Bradley Hospital, a non-profit psychiatric hospital, to characterize hormone sensitivity in adolescent females. The study aims to examine the effects of ovarian steroid hormones, particularly estrogen, on mood and sleep problems in adolescent girls aged 11-14 who are at least one year post-menarche and have...